Great Point Partners Llc Buys Concert Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, PTC Therapeutics Inc, Sells Enanta Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, CoLucid Pharmaceuticals Inc

Greenwich, CT, based Investment company Great Point Partners Llc buys Concert Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, PTC Therapeutics Inc, Synergy Pharmaceuticals Inc, Paratek Pharmaceuticals Inc, NeuroDerm, Acceleron Pharma Inc, Aurinia Pharmaceuticals Inc, Five Prime Therapeutics Inc, Blueprint Medicines Corp, sells Enanta Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, CoLucid Pharmaceuticals Inc, Trevena Inc, AveXis Inc during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Great Point Partners Llc. As of 2017-03-31, Great Point Partners Llc owns 37 stocks with a total value of $504 million. These are the details of the buys and sells.

For the details of GREAT POINT PARTNERS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=GREAT+POINT+PARTNERS+LLC

These are the top 5 holdings of GREAT POINT PARTNERS LLC
  1. Adamas Pharmaceuticals Inc (ADMS) - 2,601,351 shares, 9.04% of the total portfolio.
  2. Concert Pharmaceuticals Inc (CNCE) - 2,200,000 shares, 7.45% of the total portfolio. New Position
  3. Synergy Pharmaceuticals Inc (SGYP) - 7,223,509 shares, 6.69% of the total portfolio. Shares added by 45.24%
  4. Vanda Pharmaceuticals Inc (VNDA) - 2,232,238 shares, 6.21% of the total portfolio. Shares added by 11.06%
  5. Rigel Pharmaceuticals Inc (RIGL) - 9,105,691 shares, 5.99% of the total portfolio. New Position
New Purchase: Concert Pharmaceuticals Inc (CNCE)

Great Point Partners Llc initiated holdings in Concert Pharmaceuticals Inc. The purchase prices were between $8.85 and $18.43, with an estimated average price of $11.99. The stock is now traded at around $13.81. The impact to the portfolio due to this purchase was 7.45%. The holdings were 2,200,000 shares as of 2017-03-31.

New Purchase: Rigel Pharmaceuticals Inc (RIGL)

Great Point Partners Llc initiated holdings in Rigel Pharmaceuticals Inc. The purchase prices were between $1.96 and $3.43, with an estimated average price of $2.55. The stock is now traded at around $2.71. The impact to the portfolio due to this purchase was 5.99%. The holdings were 9,105,691 shares as of 2017-03-31.

New Purchase: PTC Therapeutics Inc (PTCT)

Great Point Partners Llc initiated holdings in PTC Therapeutics Inc. The purchase prices were between $8.37 and $15.47, with an estimated average price of $12.1. The stock is now traded at around $17.65. The impact to the portfolio due to this purchase was 2.87%. The holdings were 1,468,521 shares as of 2017-03-31.

New Purchase: Paratek Pharmaceuticals Inc (PRTK)

Great Point Partners Llc initiated holdings in Paratek Pharmaceuticals Inc. The purchase prices were between $14.25 and $19.25, with an estimated average price of $15.76. The stock is now traded at around $23.55. The impact to the portfolio due to this purchase was 2.06%. The holdings were 539,571 shares as of 2017-03-31.

New Purchase: NeuroDerm Ltd (NDRM)

Great Point Partners Llc initiated holdings in NeuroDerm Ltd. The purchase prices were between $20.9 and $29.3, with an estimated average price of $24.77. The stock is now traded at around $28.85. The impact to the portfolio due to this purchase was 1.66%. The holdings were 314,724 shares as of 2017-03-31.

New Purchase: Acceleron Pharma Inc (XLRN)

Great Point Partners Llc initiated holdings in Acceleron Pharma Inc. The purchase prices were between $23.3 and $30.17, with an estimated average price of $26.35. The stock is now traded at around $32.43. The impact to the portfolio due to this purchase was 1.58%. The holdings were 300,000 shares as of 2017-03-31.

Added: Synergy Pharmaceuticals Inc (SGYP)

Great Point Partners Llc added to the holdings in Synergy Pharmaceuticals Inc by 45.24%. The purchase prices were between $4.47 and $7.07, with an estimated average price of $5.8. The stock is now traded at around $4.52. The impact to the portfolio due to this purchase was 2.08%. The holdings were 7,223,509 shares as of 2017-03-31.

Added: DBV Technologies SA (DBVT)

Great Point Partners Llc added to the holdings in DBV Technologies SA by 31.33%. The purchase prices were between $33.24 and $36.97, with an estimated average price of $35.09. The stock is now traded at around $34.94. The impact to the portfolio due to this purchase was 0.81%. The holdings were 485,915 shares as of 2017-03-31.

Added: Foamix Pharmaceuticals Ltd (FOMX)

Great Point Partners Llc added to the holdings in Foamix Pharmaceuticals Ltd by 22.72%. The purchase prices were between $4.87 and $11.14, with an estimated average price of $9.62. The stock is now traded at around $4.34. The impact to the portfolio due to this purchase was 0.67%. The holdings were 3,681,708 shares as of 2017-03-31.

Sold Out: Enanta Pharmaceuticals Inc (ENTA)

Great Point Partners Llc sold out the holdings in Enanta Pharmaceuticals Inc. The sale prices were between $27.72 and $36.05, with an estimated average price of $31.14.

Sold Out: Merrimack Pharmaceuticals Inc (MACK)

Great Point Partners Llc sold out the holdings in Merrimack Pharmaceuticals Inc. The sale prices were between $2.98 and $4.09, with an estimated average price of $3.18.

Sold Out: CoLucid Pharmaceuticals Inc (CLCD)

Great Point Partners Llc sold out the holdings in CoLucid Pharmaceuticals Inc. The sale prices were between $31.95 and $46.53, with an estimated average price of $43.26.

Sold Out: Inotek Pharmaceuticals Corp (ITEK)

Great Point Partners Llc sold out the holdings in Inotek Pharmaceuticals Corp. The sale prices were between $1.53 and $2.15, with an estimated average price of $1.68.

Sold Out: ACADIA Pharmaceuticals Inc (ACAD)

Great Point Partners Llc sold out the holdings in ACADIA Pharmaceuticals Inc. The sale prices were between $28.77 and $39.85, with an estimated average price of $35.3.

Sold Out: Ocera Therapeutics Inc (OCRX)

Great Point Partners Llc sold out the holdings in Ocera Therapeutics Inc. The sale prices were between $0.55 and $2.25, with an estimated average price of $1.27.

Reduced: Trevena Inc (TRVN)

Great Point Partners Llc reduced to the holdings in Trevena Inc by 88.73%. The sale prices were between $3.33 and $7.94, with an estimated average price of $5.45. The stock is now traded at around $2.45. The impact to the portfolio due to this sale was -3.21%. Great Point Partners Llc still held 338,292 shares as of 2017-03-31.

Reduced: AveXis Inc (AVXS)

Great Point Partners Llc reduced to the holdings in AveXis Inc by 51.59%. The sale prices were between $47.26 and $84, with an estimated average price of $61.9. The stock is now traded at around $76.13. The impact to the portfolio due to this sale was -2.09%. Great Point Partners Llc still held 200,000 shares as of 2017-03-31.

Reduced: Global Blood Therapeutics Inc (GBT)

Great Point Partners Llc reduced to the holdings in Global Blood Therapeutics Inc by 70%. The sale prices were between $14.3 and $39.55, with an estimated average price of $25.19. The stock is now traded at around $30.75. The impact to the portfolio due to this sale was -2.08%. Great Point Partners Llc still held 300,000 shares as of 2017-03-31.

Reduced: Neurocrine Biosciences Inc (NBIX)

Great Point Partners Llc reduced to the holdings in Neurocrine Biosciences Inc by 25.33%. The sale prices were between $38.66 and $47.26, with an estimated average price of $42.84. The stock is now traded at around $47.47. The impact to the portfolio due to this sale was -1.51%. Great Point Partners Llc still held 560,000 shares as of 2017-03-31.

Reduced: Ignyta Inc (RXDX)

Great Point Partners Llc reduced to the holdings in Ignyta Inc by 23.22%. The sale prices were between $4.85 and $9.6, with an estimated average price of $7.31. The stock is now traded at around $10.00. The impact to the portfolio due to this sale was -1.01%. Great Point Partners Llc still held 3,071,300 shares as of 2017-03-31.

Reduced: Sage Therapeutics Inc (SAGE)

Great Point Partners Llc reduced to the holdings in Sage Therapeutics Inc by 21.75%. The sale prices were between $46.01 and $71.07, with an estimated average price of $58.58. The stock is now traded at around $83.31. The impact to the portfolio due to this sale was -0.88%. Great Point Partners Llc still held 301,809 shares as of 2017-03-31.



Here is the complete portfolio of GREAT POINT PARTNERS LLC. Also check out:

1. GREAT POINT PARTNERS LLC's Undervalued Stocks
2. GREAT POINT PARTNERS LLC's Top Growth Companies, and
3. GREAT POINT PARTNERS LLC's High Yield stocks
4. Stocks that GREAT POINT PARTNERS LLC keeps buying